GLP-1 Drug Dulaglutide Linked to Rare Vision Loss That Reversed After Stopping
Two patients developed rare choroidal eye disease on dulaglutide; vision fully recovered after stopping the GLP-1 drug.
Summary
Two patients taking dulaglutide (Trulicity), a GLP-1 receptor agonist used for diabetes and weight management, developed a rare eye condition called choroidal lymphoid hyperplasia (CLH) that caused vision loss within 2-3 months of starting the drug. Both patients saw their vision return to normal within days to weeks of stopping dulaglutide. The condition — a benign but potentially serious proliferation of immune cells in the eye — is poorly understood, and researchers have no clear explanation for why the drug may have triggered it. Doctors publishing in the New England Journal of Medicine stress this appears exceedingly rare, but emphasize that recognizing and stopping the drug promptly leads to full recovery. GLP-1 drugs have previously been linked to other eye-related concerns, including a type of optic nerve injury.
Detailed Summary
GLP-1 receptor agonists like semaglutide and dulaglutide have transformed diabetes and obesity treatment, but a growing body of evidence suggests these drugs may carry underappreciated risks for eye health. The latest concern involves choroidal lymphoid hyperplasia, a rare benign proliferation of immune cells inside the eye that can impair vision.
Two patients — a 47-year-old man and a second unspecified patient — developed blurry vision in one eye after 2-3 months on dulaglutide (Trulicity). Imaging confirmed choroidal and retinal abnormalities, and one patient also showed lymph node swelling throughout the body. A biopsy confirmed lymphoid hyperplasia. Standard treatments including steroids provided only temporary relief until dulaglutide was stopped, after which vision normalized within 10 days to one month.
The findings, published as a correspondence in the New England Journal of Medicine by researchers at Memorial Sloan Kettering Cancer Center, stop short of proving causation. The biological mechanism is entirely unknown. Researchers speculate that CLH may involve an abnormal immune or antigenic response, but cannot explain why a GLP-1 agonist would provoke it. No additional cases have been identified since.
This report adds to a broader pattern of ocular signals associated with GLP-1 drugs. Multiple studies have flagged a possible link to nonarteritic anterior ischemic optic neuropathy (NAION), prompting the European Medicines Agency to recommend updated safety labeling for semaglutide. Evidence on diabetic retinopathy remains mixed, while some data suggest GLP-1s may actually protect against age-related macular degeneration.
For the health-conscious adult taking or considering GLP-1 therapy, the practical message is clear: unexplained new vision changes during GLP-1 treatment warrant prompt ophthalmology evaluation. Discontinuation appears to be both the diagnostic test and the cure for CLH. Given the massive global use of these drugs, even rare adverse events deserve clinical awareness.
Key Findings
- Two dulaglutide users developed rare choroidal eye disease causing vision loss within 2-3 months of starting treatment.
- Vision fully normalized within 10 days to 1 month after stopping the GLP-1 drug in both patients.
- Biological mechanism is unknown; researchers suspect an immune-mediated response but have no confirmed explanation.
- GLP-1 drugs have been linked to multiple eye conditions including NAION, with mixed evidence across studies.
- Condition is described as exceedingly rare but reversible if recognized and drug is discontinued promptly.
Methodology
This is a news report summarizing a brief clinical correspondence published in the New England Journal of Medicine, one of the highest-credibility medical journals. The evidence basis is a two-patient case series, which is the lowest tier of clinical evidence and insufficient to establish causation. The report is authored by oncology ophthalmologists at Memorial Sloan Kettering Cancer Center.
Study Limitations
Only two cases are reported, making it impossible to establish causality or estimate true incidence. The mechanism is entirely unknown and the association could be coincidental. Readers should consult the original NEJM correspondence for full clinical detail and await larger pharmacovigilance studies before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.